Phase I trial of adjuvant mature autologous dendritic cell/allogeneic tumor lysate vaccines in combination with temozolomide in newly diagnosed glioblastoma (Jun 2022)
Novel strategy for manufacturing autologous dendritic cell/allogeneic tumor lysate vaccines for glioblastoma (Aug 2020)
Adenovirus platform enhances transduction efficiency of human mesenchymal stem cells: An opportunity for cellular carriers of targeted TRAIL-based TR3 biologics in ovarian cancer (Dec 2017)
p53 pathway dysfunction is highly prevalent in acute myeloid leukemia independent of TP53 mutational status (Jun 2017)
Optimizing patient derived mesenchymal stem cells as virus carriers for a Phase I clinical trial in ovarian cancer (Jan 2013)
